Smith S J, Markandu N D, Sagnella G A, MacGregor G A
Br Med J (Clin Res Ed). 1985 Jan 12;290(6462):110-3. doi: 10.1136/bmj.290.6462.110.
Twenty patients with mild or moderate essential hypertension and not receiving any drug treatment, who had been moderately restricting their sodium intake to around 70 mmol(mEq) a day for at least one month and whose mean blood pressure was then 163/103 mm Hg, were entered into a double blind, randomised crossover study to compare one month's treatment with slow release potassium chloride tablets (64 mmol potassium chloride a day) with one month's treatment with a matching placebo. Mean (SEM) urinary sodium excretion on entry to the study was 68 (6.8) mmol/24 h. Mean urinary potassium excretion increased from 67 (6.9) mmol(mEq)/24 h with placebo to 117 (4.6) mmol/24 h with potassium chloride. Supine and standing systolic and diastolic blood pressures did not change significantly with potassium chloride supplementation when compared with pressures while receiving placebo or before randomisation. In patients who are able moderately to restrict their sodium intake doubling potassium as a chloride salt has little or no effect on blood pressure.
20例轻度或中度原发性高血压患者,未接受任何药物治疗,至少1个月来适度限制钠摄入量至每日约70 mmol(mEq),此时平均血压为163/103 mmHg,进入一项双盲、随机交叉研究,比较服用缓释氯化钾片(每日64 mmol氯化钾)1个月的治疗与服用匹配安慰剂1个月的治疗效果。研究开始时平均(SEM)尿钠排泄量为68(6.8)mmol/24小时。平均尿钾排泄量从服用安慰剂时的67(6.9)mmol(mEq)/24小时增加到服用氯化钾时的117(4.6)mmol/24小时。与服用安慰剂时或随机分组前的血压相比,补充氯化钾时仰卧位和站立位的收缩压和舒张压无显著变化。对于能够适度限制钠摄入量的患者,将钾作为氯盐加倍摄入对血压几乎没有影响。